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INTRODUCTION
Asthma is a reversible and variable airflow obstruction caused 
by chronic airway inflammation. Numerous laboratory and ep-
idemiological studies have focused on the etiology and mecha-
nistic pathways of asthma, in order to improve diagnosis, thera-
py, and prognosis. Although these efforts have significantly ad-
vanced asthma care, particularly therapy, more work is needed 
to accomplish these goals. In addition, despite the significant 
proportion of people worldwide who are affected by asthma or 
other atopic conditions, little effort has been made in assessing 
and addressing the impact of asthma on the epidemiology of 
other diseases. Research by our group and others has suggest-
ed a potential impact of asthma on susceptibility to other dis-
eases. We postulate that the immunogenetic underpinning of 
atopic diseases is related to mechanisms underlying an in-
creased risk for other diseases in those with asthma and other 
atopic diseases.
In this paper, the author makes a case that clinically defined 
asthma or immunogenetic predisposition to asthma may influ-
ence susceptibility to other diseases and suggests that research 
efforts to identify the etiology of asthma must be juxtaposed to 
those examining the effects of asthma on various health out-
comes. This approach will not only improve asthma care but 
also enhance efforts to identify the etiology and mechanistic 
pathways of asthma, because both the etiology and effects of 
asthma are likely to share the same immunological underpin-
nings.
The present paper focuses on a primary discussion on the im-
pact of asthma on the risk for microbial infections, using exam-
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ples of emerging and re-emerging microbial infections, and 
briefly touches upon the contribution of other atopic conditions 
to the risk for microbial infections. Subsequently, this discus-
sion is expanded to the risk for chronic pro-inflammatory con-
ditions. Then, the potential mechanisms underlying the associ-
ation between asthma and other diseases are briefly explored. 
The final section presents the implications of the scope of this 
paper related to patient care, research, and public health.
ASTHMA EPIDEMIOLOGY AND THE BURDEN OF THE 
DISEASE
Asthma is the most common chronic childhood illness and a 
major cause of morbidity in adults, afflicting 9.6%-13% of chil-
dren
1,2 and 7.7%-10.1% of adults in the U.S.
2,3 Nearly 30 million 
Americans and 300 million people worldwide are affected by 
asthma.
4 A similar asthma incidence has been observed in Ol-
msted County, Minnesota.
5,6 Based on medical record reviews 
for 3,059 children, Yawn et al.
6 reported that the prevalence of 
ever-diagnosed asthma among children in grades K-12 in Roch-
ester (MN, USA) was 17.9% in 1999. There is a debate regarding 
whether increased asthma prevalence truly exists or is the re-
sult of enhanced recognition or changes in diagnostic codes. 
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However, given the improved asthma treatment and access to 
general medical care, the significant increase of asthma mortal-
ity over the past three decades in the U.S. suggests a true increase 
of asthma prevalence.
7-9 At present, there are no overall signs of 
a declining trend in asthma prevalence; rather, asthma contin-
ues to increase in many parts of the world.
10 In addition, other 
atopic conditions, which share many of the same underlying 
mechanisms, have prevalence trends similar to that of asthma. 
For example, studies have reported a significant increase in the 
prevalence of atopic dermatitis throughout the world.
11,12 In the 
U.S., the prevalence of atopic dermatitis is 10%-19%,
13-15 affect-
ing 17.8-31.6 million people depending on the criteria for ecze-
ma.
13 Allergic rhinitis is also seen in a significant proportion of 
people in the U.S. (26%-33%; approximately 60 million peo-
ple).
13-16 Considering the significant proportion of the popula-
tion affected by asthma and other atopic conditions, determin-
ing the impact of asthma on the risk for other diseases at a pop-
ulation level is advisable.
IMPACT OF ASTHMA ON THE RISK FOR RE-EMERGING 
MICROBIAL INFECTIONS
This section discusses the impact of asthma on the risk for in-
fections caused by Streptococcus pneumonia and Bordetella 
pertussis (B. pertussis), and for mumps, as examples of re-emerg-
ing microbial infections.
Asthma and the risk for serious pneumococcal infection
Despite the trend toward reduced risk for invasive pneumo-
coccal diseases (IPD) caused by the heptavalent pneumococcal 
conjugate vaccine serotypes in the U.S.,
17-19 Streptococcus pneu-
moniae (S. pneumoniae) continues to present a global threat of 
significant morbidity and mortality among both children and 
adults. For example, because of emerging serotype replace-
ment,
20 the Advisory Committee on Immunization Practices 
(ACIP) of the U.S. Centers for Disease Control and Prevention 
(CDC) now recommends the 13-valent pneumococcal conju-
gate vaccine for all children. Given the increasing number of 
pneumococci serotypes, it is difficult to predict whether vac-
cine manufacturers will continue to keep up with serotype re-
placement in the future. Neither natural disease nor vaccina-
tion provides complete or life-long immunity against reinfec-
tion or new disease. Globally, one million children younger than 
5 years of age die from pneumonia and IPD each year.
21 In the 
U.S., the annual number of fatal pneumococcal infections is 
40,000.
22 S. pneumoniae is responsible for six million cases of 
otitis media, 100,000 cases of pneumonia, 60,000 cases of sep-
sis, and 3,300 cases of meningitis per year in the U.S., and naso-
pharyngeal colonization, a prelude to IPD, occurs in 20%-50% 
of the population. IPD has a 10% fatality rate for all reported cas-
es (1,556 deaths/15,544 cases). Previous studies have reported 
that only 50.6% of individuals who developed IPD had at least 
one known indication for either the pneumococcal polysaccha-
ride or conjugate vaccine.
23 This indicates that nearly half of IPD 
cases do not display identifiable risk factors for IPD, suggesting 
the existence of unidentified risk factors for IPD.
Two recent studies have addressed this question. In 2005, Tal-
bot et al.
24 conducted a case-control study to assess the relation-
ship between asthma and IPD among Medicaid enrollees (chil-
dren and adults) of the State of Tennessee, using the Active Bac-
terial Surveillance Program database (1995-2002) of the CDC 
and the State’s administrative Medicaid database. They report-
ed that asthma was significantly associated with the risk for IPD 
(Odd Ratio [OR], 2.4; 95% Confidence Interval [CI], 1.9-3.2) af-
ter adjusting for pertinent covariates and confounders such as 
high-risk conditions for IPD.
24 The population attributable risk 
percentage (PAR%) in adults was estimated to be 11%. In an in-
dependent population-based case-control study conducted in 
2008, our research group found that adults with asthma were at 
significantly increased risk for serious pneumococcal diseases 
(SPDs) (IPD and/or pneumococcal pneumonia) compared 
with adults without asthma (OR, 6.7; 95% CI, 1.6-27.3; P=0.01), 
after controlling for high-risk conditions for IPD and smoking 
exposure.
25 The PAR% was 17% in the adult population, where-
as the PAR% for all combined ACIP vaccine-eligible conditions 
in adults was 24%. These data suggest that asthma status alone 
disproportionately increases the burden of SPD at the popula-
tion level. As a result of these two studies, the ACIP now recom-
mends a 23-valent pneumococcal polysaccharide vaccine for 
adults aged 19-64 years who have asthma.
Asthma and the risk for Bordetella pertussis
B. pertussis causes whooping cough, a serious respiratory in-
fection affecting 800,000 to 3.3 million people in the U.S. and 50 
million worldwide, and causing 300,000 deaths annually.
26-28 B. 
pertussis continues to be a major public health concern, despite 
the availability of a pertussis vaccine and efforts to improve vac-
cine uptake. A recent outbreak of nearly 10,000 pertussis cases, 
as reported to the California Department of Public Health in 
2010,
29 highlights the persistence of pertussis as a major threat 
to public health. During the 1980s and 1990s, pertussis affected 
primarily infants.
30 During the 2000s, adolescents and adults 
were disproportionately affected. Among children 10-19 years 
old, the incidence increased from 5.5 per 100,000 in 2001 to 10.9 
per 100,000 in 2003. These data suggest an increase in pertussis 
incidence due primarily to the waning of humoral immunity 
over time.
Recently, we reported preliminary results showing an increased 
risk for pertussis among people with asthma, based on a per-
tussis outbreak in Olmsted County, Minnesota.
31 The OR for the 
association between asthma and the risk for pertussis was 1.70 
(95% CI, 1.03-2.79; P=0.036); the PAR% of asthma was 15.6%. 
No population-based study exists for comparison with our pre-
liminary results, but descriptive studies have suggested a po-Juhn
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tential association between asthma and pertussis.
32,33 The im-
pact of asthma on pertussis epidemiology at the population lev-
el is yet to be determined, and it is important to continue to 
monitor this association.
Asthma and the risk for mumps virus infection
Despite a high vaccine uptake with two doses of mumps vac-
cine, a large mumps outbreak occurred in the U.S. in 2006.
34,35 A 
total of 6,584 mumps cases were reported in 2006, but there were 
no deaths related to the outbreak.
35 This mumps outbreak rais-
es a significant public health concern, as it occurred despite 
high MMR vaccine coverage. In 2006, the national two-dose 
coverage among adolescents, who are the highest risk group 
during a mumps outbreak, was 87%, the highest in U.S. histo-
ry.
35 Failure of the two-dose vaccine calls for the development 
of a more effective vaccine or a change in vaccine policy. Nev-
ertheless, neither the public health agencies nor the research 
community have paid attention to why immunity against the 
mumps virus diminishes more rapidly than other immunities, 
and little effort has been made to identify the selective groups 
at risk for rapid loss of immunity. Previous studies have report-
ed that a significant proportion of asthmatics aged 1.6-17 years 
who had received two doses of MMR became seronegative for 
measles (40%-43%) and mumps (25%-39%) immunity.
36 In ad-
dition, we recently showed that asthmatic children and adoles-
cents with a family history of asthma had poorer lymphoprolif-
erative responses (a measure of cell-mediated immunity) to 
mumps and rubella vaccine viruses compared with those with-
out asthma.
37 Previous studies have suggested a temporal wan-
ing of anti-rubella antibodies (2.4% decrease per year); thus, 
without a booster vaccination, individuals may eventually be-
come susceptible to rubella or other viral infections.
38 Our re-
search group recently demonstrated a more rapid decrease of 
measles virus-specific IgG levels over time in asthmatics com-
pared with non-asthmatics.
39
Taken together, these studies suggest that asthmatics may lose 
immunity against mumps or other viruses more rapidly than 
non-asthmatics and may become a population susceptible to 
outbreaks of serious infectious diseases. Therefore, a potential 
epidemiological relationship may exist between asthma preva-
lence and the 2006 outbreak of mumps in the U.S. This is a re-
search area that deserves further investigation in order to assess 
whether asthma or other atopic conditions represent an unrec-
ognized selective risk group who require individualized immu-
nization schedules or should be targeted before and during an 
outbreak, e.g., by sero-surveillance during routine asthma care.
IMPACT OF ASTHMA ON THE RISK FOR EMERGING 
MICROBIAL INFECTIONS
Asthma may play a role in the risk for new emerging microbial 
infections such as the 2009 pandemic of novel H1N1 influenza 
virus infection. This section illustrates the impact of asthma sta-
tus on the risk for and severity of novel H1N1 influenza infec-
tion by discussing the literature.
On June 11, 2009, the World Health Organization (WHO) de-
clared the first influenza pandemic in 41 years. The WHO re-
ported that as of July 25, 2010, more than 214 countries had been 
affected by H1N1 influenza, resulting in at least 18,398 deaths 
worldwide.
40 As of October 2009 (the end of the 2008-2009 in-
fluenza season), the CDC reported 50,768 cases of H1N1 influ-
enza in the U.S. Seventy-six (51.7%) deaths were attributed to 
H1N1 influenza infection.
41
Although H1N1 influenza infection might not have appeared 
to be clinically severe, the epidemiological severity of H1N1 in-
fluenza was greater than that of seasonal influenza. For exam-
ple, using “years of life lost” to compare epidemiologic, the 
2009 H1N1 pandemic ranks between the 1968 and 1957 sea-
sonal influenza pandemics, and its social impact in terms of 
missed work days and school days may exceed the social im-
pact of these earlier pandemics.
42
Our research group carefully examined the studies published 
during and after the H1N1 influenza pandemic to help assess 
whether asthmatics displayed an increased risk for and severity 
of H1N1 influenza infection. During the H1N1 influenza pan-
demic, two independent studies conducted in the U.S. and 
Australia-New Zealand showed that the majority of individuals 
(73%) who developed severe H1N1 influenza (i.e., were admit-
ted to the inpatient floor or intensive care unit) had underlying 
chronic conditions, with asthma being the most common co-
morbid condition (28% and 32.7% in the U.S. and Australia-New 
Zealand studies, respectively).
43,44 In addition, Kloepfer et al.
45 
recently reported that compared with non-asthmatics, asth-
matics displayed an increased risk for H1N1 influenza infection. 
Therefore, asthma might have played an important role in the 
epidemiology of the H1N1 influenza infection.
ATOPIC CONDITIONS OTHER THAN ASTHMA AND THE 
RISK FOR MICROBIAL INFECTIONS
Atopic conditions other than asthma, including atopic der-
matitis and allergic rhinitis, may also affect the risk for microbi-
al infections, as these conditions and asthma share the same 
underlying immunological mechanisms (i.e., T helper 2 cell-
predominant immune profiles).
Atopic dermatitis/allergic rhinitis and the risk for serious 
pneumococcal disease
After observing the association between asthma and the risk 
for SPD, we extended our study to assess the role of atopic con-
ditions other than asthma in increasing the risk for SPD.
46 The 
adjusted odds ratio for the association between atopic condi-
tions other than asthma and SPD was 2.13 (95% CI, 1.04-4.35; 
P=0.04) after taking into account smoking status, high-risk Influence of Asthma Epidemiology
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conditions for IPD, education status, ethnicity, and asthma sta-
tus. Thus, like patients with asthma, individuals with other atop-
ic conditions may have increased risk for SPD, independent of 
asthma status. These results also suggest that the increased risk 
for SPD in patients with asthma may not be entirely attributable 
to altered airway architecture; the potentially altered immune 
functions shared by patients with asthma and those with other 
atopic conditions may contribute to the increased risk.
Atopic dermatitis/allergic rhinitis and the risk for 
Streptococcus pyogenes infection
We further extended our work to assess the potential associa-
tion between atopic conditions and other streptococcal infec-
tions such as Streptococcus pyogenes (S. pyogenes).
47,48 Patients 
with asthma showed a higher incidence of S. pyogenes infection 
or colonization (0.25 per person-year; RR, 1.38; 95% CI, 1.12-1.7; 
P=0.003) compared with non-asthmatic patients (0.18 per per-
son-year). Similarly, patients with other atopic conditions (atop-
ic dermatitis and/or allergic rhinitis) displayed a higher inci-
dence of S. pyogenes infection (0.24 per person-year; RR, 1.36; 
95% CI, 1.12-1.67; P=0.004) compared with non-atopic patients 
(0.17 per person-year) after adjusting for asthma status. These 
results suggest that patients with either asthma or another atop-
ic condition have increased susceptibility to S. pyogenes infec-
tions.
Lessons learned from the data
This paper presents several noteworthy findings. First, the in-
creased risk for microbial infections among individuals with 
atopic conditions other than asthma suggests that the impair-
ment of certain immune functions in asthmatics may play a 
role in increasing the risk for microbial infection. Recently, our 
research group showed suboptimal anti-pneumococcal anti-
body titers in asthmatics compared with non-asthmatics.
49 The 
literature also shows impaired innate and adaptive immune 
functions in asthmatics and other atopics (i.e., impaired in-
nate
50-53 and adaptive immunity
54-56). Second, the data regard-
ing the association between asthma and the risk for microbial 
infections suggest that an immunogenetic predisposition to 
asthma poses an increased risk for microbial infections even 
prior to the development of clinically defined asthma.
47,48 Thus, 
previous findings on the association between increased bacte-
rial colonization of the airways in infants and subsequent de-
velopment of asthma at the age of 5 years could be interpreted 
with reverse causality.
57 In this respect, the relationship between 
the genetic risk for atopy and a defect in immune cell develop-
ment leading to immune incompetence may warrant further 
investigation.
58 Third, the potentially altered immune function 
in asthmatics and atopics suggests that immune dysregulation 
may change the risk for non-infectious chronic diseases such as 
inflammatory bowel syndrome, rheumatoid arthritis, diabetes, 
and coronary heart disease.
POTENTIAL BIASES AND CONFOUNDERS FOR THE 
ASSOCIATION
When assessing the association between asthma and the risk 
for other diseases, systematic biases must be investigated, in-
cluding detection bias stemming from a situation where the ex-
posure status influences the detection of outcomes and the po-
tential influence of systemic or inhaled corticosteroids on the 
susceptibility to microbial infection.
Detection bias
The detection of SPD is unlikely to be susceptible to bias, giv-
en the serious nature of the disease. However, for other micro-
bial infections, patients with asthma may be more likely to seek 
medical evaluation for upper respiratory symptoms, and clini-
cians may be more likely to seek tests or other evaluations in 
patients with asthma compared with non-asthmatic patients; 
our research group extensively addressed this concern in previ-
ous work.
47,48,59 In a prospective cohort study following 115 chil-
dren (<4 years of age) for approximately 6 months, we found 
that the asthma status of the children was not associated with 
the likelihood of seeking medical evaluation for acute respira-
tory or gastrointestinal illnesses; the correlation between the 
frequency of illness and the frequency of seeking care was al-
most identical between children with and without asthma (ρ: 
0.62, P<0.001 vs. ρ: 0.64, P<0.001, respectively).
59 We recently 
updated these data by further following the original study co-
hort, and the proportion of medical evaluations per acute ill-
ness among asthmatic and non-asthmatic subjects were 0.41 
and 0.39, respectively (P=0.75).
60 These results indicate that the 
parents of asthmatic children are similar to those of non-asth-
matic children with regard to the likelihood of seeking medical 
evaluation for their acutely ill children. We also compared the 
incidence of S. pyogenes infection and the incidence of testing 
for S. pyogenes before and after physician diagnosis of asthma. 
The incidence of S. pyogenes infection did not differ between 
before and after the diagnosis of asthma (0.28 vs. 0.24 per year, 
respectively; P=0.37), nor did the incidence of testing for S. pyo-
genes infection (0.92 vs. 0.89 per year, respectively; P=0.74).
47 
Thus, a detection bias is unlikely to entirely explain the relation-
ship between asthma and microbial infections.
Influence of corticosteroid treatment on the risk for microbial 
infection in asthmatics
Although the literature suggests a potential impact of inhaled 
corticosteroids on the risk for infection in patients with COPD, 
this observation has not been well established in patients with 
asthma.
61,62 In the study results described above, few asthmatic 
subjects were receiving systemic or inhaled corticosteroids; thus, 
exposure to corticosteroids is unlikely to account for the find-
ings. In the literature, corticosteroid therapy has not been con-
sistently and significantly shown to be associated with poorer Juhn
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humoral or cell-mediated responses to vaccines.
63-66 Amid the 
concern regarding the potential impact of inhaled corticoste-
roid therapy on the risk for infection, noteworthy findings have 
been reported. Doull et al.
67 showed no significant benefits 
from inhaled corticosteroid therapy for viral infection-induced 
wheezing. In their study, they assessed the percentage of days 
of upper and lower respiratory tract infection between an in-
haled corticosteroid treatment group and placebo group before 
and after therapy. Although no significant differences between 
the groups was observed for the frequency of viral infections, 
post-therapy outcome measures showed a significant reduc-
tion in the percentage of days of upper respiratory tract infec-
tion (21 to 10 vs. 19 to 16, respectively) and of lower respiratory 
tract infection (30 to 15 vs. 27 to 21) after inhaled corticosteroid 
therapy compared with the placebo group. The findings of a 
potential benefit of inhaled corticosteroids in reducing upper 
or lower respiratory tract infections did not draw full attention, 
as the study addressed only the study aims by accepting the null 
hypothesis (no significant difference) and did not examine ei-
ther side of the hypothesis testing. Thus, the only conclusions 
drawn were of no overall increases of infection among subjects 
treated with inhaled corticosteroids, reassuring patients and 
clinicians of the safety of inhaled corticosteroids.
Similarly, Martin et al.
68 examined the association between 
asthma and chronic infections with mycoplasma and Chlamyd-
ia. Although a strong association between asthma and infec-
tions with mycoplasma and Chlamydia existed, patients on ste-
roid therapy at the time of study enrollment showed a lower fre-
quency of mycoplasma and Chlamydia infections compared to 
those without steroid therapy. Based on the provided informa-
tion, an odds ratio for the association between steroid therapy 
and the risk for mycoplasma or Chlamydia infection was esti-
mated to be 0.34 (P=0.068), suggesting a potential protective 
effect on the risk for such infections.
While corticosteroid therapies, particularly a burst course of 
systemic steroid therapy and inhaled corticosteroid treatment, 
do not appear to increase the risk for microbial infections, the 
literature may not fully address this issue, as the concerns or 
aims of previous studies have tended to focus on rejecting an 
alternative hypothesis (accepting the null hypothesis, support-
ing no difference in the risk for infection between comparison 
groups). In summary, the association of asthma and other atop-
ic conditions with the risk for microbial infections is unlikely to 
be fully accounted for by corticosteroid therapies.
IMPACT OF ASTHMA ON THE RISK FOR NON-
INFECTIOUS PRO-INFLAMMATORY CHRONIC DISEASES
As discussed above, it is not known whether potential altera-
tions in immune function (i.e., immune dysregulation) in asth-
matics and other atopics can result in a predisposition to non-
infectious chronic diseases. Sporadic investigations have been 
conducted using different study designs, various definitions of 
asthma and other atopic conditions, and different study sub-
jects and settings. To address this question, our research group 
recently conducted a population-based matched cohort study 
to assess whether asthma is associated with the risk for devel-
oping inflammatory bowel disease, rheumatoid arthritis, dia-
betes, and coronary heart disease.
69 Asthma was associated 
with an increased risk for developing diabetes (HR, 2.11; 95% 
CI, 1.43-3.13; P<0.001) and coronary heart disease (HR, 1.47; 
95% CI, 1.05-2.06; P=0.024), but not with an increased risk for 
inflammatory bowel disease (HR, 1.31; P=0.56) or rheumatoid 
arthritis (HR, 1.30; P=0.31). Previous studies have demonstrat-
ed an association between asthma and both coronary heart 
disease
70 and diabetes.
70-73 The lack of an association between 
asthma and inflammatory bowel disease and rheumatoid ar-
thritis may be related to systemic corticosteroid therapies in 
asthmatics. The study was conducted between 1964 and 1983, 
when systemic steroids were often used for the treatment of 
asthma, and steroid treatments might have alleviated the prog-
ress of inflammatory bowel disease or rheumatoid arthritis. 
Nevertheless, the data clearly suggest that despite the recipro-
cal inhibitory relationship between Th1 and Th2 cells at the im-
munological level, asthma as a Th2-predominant condition 
does not confer a protective effect on Th1-predominant pro-in-
flammatory conditions, but may increase the risk for other con-
ditions.
POTENTIAL MECHANISMS UNDERLYING THE 
ASSOCIATION BETWEEN ASTHMA AND OTHER DISEASES
Conceptualizing the mechanisms underlying the association 
of asthma with microbial infections and non-infectious pro-in-
flammatory chronic conditions is not a simple task, given the 
multiple requirements accounting for the association. If asth-
ma were to causally affect the risk for other diseases, it appears 
clear that alterations in airway architecture and the previously 
reported impairments of innate immunity in asthmatics would 
unlikely be sufficient to account for the associations, given that 
adaptive immune functions are probably involved with the pro-
cesses discussed above (e.g., the waning of immunity, subopti-
mal cell-mediated immunity, and involvement with other in-
flammatory diseases). Indeed, the literature provides some spo-
radic support for altered or impaired adaptive immune func-
tions in asthmatics and other atopics.
54-56 The mechanisms un-
derlying the association between asthma and other diseases 
are likely to be related to the immunogenetic underpinnings of 
atopy. A Th2-predominant immune environment has been 
shown to be associated with susceptibility to and severity of a 
broad range of microbial infections, including Gram-negative 
bacteria,
74,75 virus,
76-79 protozoa,
80-82 mycoplasma,
83 and candidi-
asis,
84 in animal models. However, the ways in which the Th2-
predominant immune milieu or cytokines affect the risk for mi-Influence of Asthma Epidemiology
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crobial infection, as well as for other inflammatory conditions, 
has not yet been determined. Many active research studies are 
investigating the mechanisms of the increased risk for infection 
in asthmatics and other atopics.
Our research group has assessed the potential role of human 
leukocyte antigen (HLA)-DR polymorphisms in the associa-
tions described above. We previously reported an association 
between the HLA-DR3 gene and childhood asthma,
85 and dem-
onstrated that this association was independent of linkage dis-
equilibrium with the ancestral haplotype 8.1.
86 Importantly, us-
ing a humanized transgenic mouse model with no mouse MHC 
genes and carrying the HLA-DR3 or HLA-DR2 gene, we showed 
significant Th-2 predominant airway inflammation and immune 
responses after sensitization and challenge with house dust 
mite (a significant increase of eosinophils and IL-4 in BAL) in 
DR3-carrying mice compared with DR2-carrying mice (the DR2 
gene was not associated with asthma, according to our epide-
miologic study).
87 These data suggest a potential HLA-DR re-
striction for recognizing house dust mite. In support of this 
finding, the HLA-DR3 gene has been reported to be associated 
with atopic asthma or allergic sensitization, including to house 
dust mite.
88-90 Other studies have suggested a HLA-D gene re-
striction for recognizing house dust mite.
91 Furthermore, a re-
cent genome-wide association study has identified the HLA-
DR gene as a susceptibility gene for asthma.
92
According to the literature, the HLA-DR3 gene is associated 
with suboptimal immune responses. Previous studies have re-
ported that HLA-DRB1*03 is associated with poor immune re-
sponses to various vaccines (measles,
93 hepatitis B,
94 and teta-
nus toxoid
95) and a nasopharyngeal carrier status of Staphylo-
coccus aureus.
96 In addition, the HLA-DR3 gene has been shown 
to be associated with a risk for autoimmune disease.
97,98 Although 
these authors did not suggest a mechanism for the association 
between asthma and the risk for other diseases, a biologically 
plausible mechanism may be explored. Different approaches 
may be used for identifying the mechanism of asthma etiology 
versus determining the effects of asthma, but the results of the 
two lines of study are likely to advance both goals. Thus, re-
search toward both goals should be performed in parallel.
THE IMPLICATIONS
Patient care
At present, current asthma care focuses on the control of asth-
ma primarily through pharmacological therapies, environmen-
tal control, and patient education. However, new approaches 
for patient care can be considered. First, the early identification 
and appropriate treatment of microbial infections or other 
chronic diseases associated with asthma may be worthwhile. 
For example, the ACIP recommendation that asthmatics aged 
19-64 years old should receive 23-valent pneumococcal poly-
saccharide vaccinations could be implemented. In addition, 
other possible causes for conditions associated with asthma 
should be evaluated. A lingering coughing episode may not be 
the result of uncontrolled asthma, but rather the result of per-
tussis, given the increased risk for pertussis in asthmatics. A 
chest pain may not be due to asthma, but may be an early man-
ifestation of coronary heart disease, given the potential associa-
tion between asthma and coronary heart disease, although the 
counteracting treatment approaches for asthma and coronary 
heart disease may be challenging. In this respect, specific rec-
ommendations for how to assess and address the conditions 
associated with asthma could be included in asthma guide-
lines. Second, along these lines, asthmatics may require indi-
vidualized immunization schedules and a specific monitoring 
plan. In the U.S., decennial Td (tetanus and diphtheria) vaccines 
after Tdap at ages 11-12 years may need to be replaced with 
Tdap for asthmatics, given the significant increase of pertussis 
among asthmatics and the major cyclic pertussis outbreaks. As-
sessment of vaccine durability (e.g., pertussis immunity or MMR 
immunity) during a routine follow-up visit for asthma care could 
be considered, and asthmatics exhibiting decreased immunity 
could receive a booster dose of vaccine. However, careful cost-
benefit and patient safety analyses must be performed before 
implementation of this approach. Finally, when new approach-
es are phased into patient care, their effectiveness needs to be 
studied through integration of both research and clinical prac-
tice.
Public health
First, when an outbreak of emerging or re-emerging infectious 
disease occurs, epidemiological investigations by public health 
agencies must assess the role of asthma or other atopic condi-
tions in the risk for or severity of infection. It would also be im-
portant to monitor the impact of asthma epidemiology on the 
epidemiology of emerging and re-emerging infectious diseases 
and of other chronic diseases. To date, little effort has been made 
to address the question of why some people acquire an infec-
tion and others do not. The role of asthma in the 2009 H1N1 in-
fluenza outbreak may represent a prime example, as discussed 
above. Second, the increased risk for microbial infections in 
asthmatics could be a biodefense or bioterrorism issue, as asth-
matics in the general population and in the military may be dis-
proportionately affected by exposure to a biological assault. Fi-
nally, it would be worthwhile for public health agencies to per-
form a well-designed surveillance for the influence of asthma 
on the epidemiology of other chronic diseases, including in-
flammatory diseases and malignancy as described above.
Research
Systematic research to clarify the association of asthma, as 
well as atopic conditions other than asthma, with microbial in-
fections, particularly vaccine-preventable infections, and chron-
ic diseases should be undertaken. Research should also address Juhn
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the question as to why some asthmatics have increased risk for 
infection and disease, while other asthmatics do not. Asthmat-
ics with increased susceptibility to microbial infections and 
other diseases may represent a different asthma phenotype, 
perhaps with different etiologic processes. This is largely over-
looked in the current literature and warrants further study. Air-
way colonization by bacteria or other organisms may provide 
an important surrogate marker for identifying asthmatics with 
a susceptibility phenotype. Our research group and others are 
actively pursuing research in this area. Finally, the identifica-
tion of a mechanism that accounts for the etiology and effects 
of asthma under a “unified theory” presents a formidable task. 
Collaborative research efforts coordinated among multidisci-
plinary research groups can increase the opportunities for per-
tinent discoveries leading to such a theory.
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